Could a common blood pressure drug shrink kidney tumors?

NCT ID NCT02104011

Terminated Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether propranolol, a beta-blocker, could shrink or stabilize kidney angiomyolipomas in people with tuberous sclerosis. Only 2 participants were enrolled before the trial was terminated, so the results are very limited. The goal was to find a less invasive alternative to surgery or embolization.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Propranolol (a beta-blocker, commonly used for high blood pressure)
What this could lead to: If it works, this could point toward a non-invasive treatment option for kidney tumors in tuberous sclerosis, potentially avoiding surgery or embolization.
What could go wrong: This was a very small pilot trial with only 2 participants and was terminated early, so results are not reliable. Beta-blockers may not shrink these tumors, and side effects like low blood pressure or fatigue are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL ANGIOMYOLIPOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney angiomyolipoma tuberous sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL ANGIOMYOLIPOMAS TUBEROUS SCLEROSIS

Contacts and locations

Show contact details

Locations

Nephrology department

Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.